
Please try another search
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC) and other chronic liver diseases in the United States. It develops Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, HDV, and HIV-1. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Morristown, New Jersey.
Name | Age | Since | Title |
---|---|---|---|
Vlad Ratziu | - | - | Member of Scientific Advisory Board |
Nikolai V. Naoumov | - | 2023 | Member of Scientific Advisory Board |
Philippe Gallay | - | 2016 | Member of Scientific Advisory Board |
Michael J. Purcell | 68 | 2024 | Independent Director |
Timothy M. Block | 70 | 2013 | Independent Director |
Stephen A. Harrison | - | 2019 | Scientific Advisory Board Chair |
Vlad Ratziu | - | 2023 | Member of Scientific Advisory Board |
Yury V. Popov | - | 2023 | Member of Scientific Advisory Board |
Rohit Loomba | - | 2023 | Member of Scientific Advisory Board |
Kaouthar Lbiati | 46 | 2022 | Interim CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review